Monday, December 23

Tag: new product

Startups Are Using AI to Predict Responses to Cancer Drugs
28Dec By adminNo Comments
World

Startups Are Using AI to Predict Responses to Cancer Drugs

Dec. 28, 2023 12:01 pm ET|WSJ ProBiomedical startups are using artificial intelligence to predict the response patients will have to cancer treatments, aiming to increase the success of drugs in clinical trials and tailor therapies to individuals.As data accumulate from clinical trials and fields such as gene and protein research, AI is helping scientists sift through large volumes of information to uncover signatures that correlate with response—or resistance—to treatment. Startups are using it to predict which drugs are likely to work in clinical studies and create tests to help doctors choose treatments.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Health Care Roundup: Market Talk
6Dec By adminNo Comments
World

Health Care Roundup: Market Talk

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0902 GMT – Merck’s failure to reach key goals in late-stage clinical trials for its multiple sclerosis drug, evobrutinib, spells an end to its development and shifts the German pharmaceutical company’s focus to cancer drug xevinapant, Citi analysts say in a note. A potential treatment for late-stage head and neck cancer, xevinapant is in phase-3 clinical trials and might be “practice-changing” if it hits the market, say the analysts. They forecast sales of more than EUR1.4 billion, which is 25% ahead of consensus, saying that it is years ahead of competitors. “While evobrutinib’s failure is an obvious setback, we had previously argued the risk-reward was ...
Read More
Bayer Shares Tumble After Clinical Trial Failure, Loss in Roundup Case
20Nov By adminNo Comments
World

Bayer Shares Tumble After Clinical Trial Failure, Loss in Roundup Case

Updated Nov. 20, 2023 3:16 pm ETBayer shares fell sharply after the company stopped a late-stage study for a blood-thinning drug early because of lack of efficacy and was told to pay $1.56 billion in a lawsuit relating to its Roundup weedkiller.Bayer said late Sunday that it discontinued a Phase 3 clinical trial to test its experimental drug asundexian for prevention of stroke and systemic embolism for patients with the heart-rhythm disorder atrial fibrillation.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Bayer Pulling Lymphoma Drug Aliqopa From U.S.
13Nov By adminNo Comments
World

Bayer Pulling Lymphoma Drug Aliqopa From U.S.

Nov. 13, 2023 10:35 am ETGerman drugs-to-crops giant Bayer is pulling Aliqopa from the U.S. after a confirmatory trial of the lymphoma drug missed its primary endpoint.Bayer on Monday said it will work with the U.S. Food and Drug Administration on a voluntary withdrawal of Aliqopa, which won accelerated approval from the agency in 2017 for adults with relapsed follicular lymphoma who have received at least two prior systemic therapies.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Novo Nordisk’s Wegovy Shows Heart Benefits Beyond Weight Loss, New Data Suggests
13Nov By adminNo Comments
World

Novo Nordisk’s Wegovy Shows Heart Benefits Beyond Weight Loss, New Data Suggests

The effectiveness of Novo Nordisk’s blockbuster obesity treatment Wegovy in reducing heart attacks and strokes could be due to more than weight loss alone, according to new clinical trial data.The surging popularity of the drug has seen the Danish pharmaceutical giant scramble to boost production as it struggles to meet demand. It has been forced to limit supply of lower-strength doses of Wegovy in the U.S. as it seeks to safeguard supplies for current patients, and has outlined plans to invest more than $6 billion to boost production capacity.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More